Kaléo has announced that it will reintroduce Auvi-Q (epinephrine injection) auto-injector to the U.S. market in the first half of...
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
Antares Pharma announced 12 week efficacy and 52 week safety results from the phase III clinical study (QST-13-003) evaluating testosterone...
Kaléo, a privately held U.S. pharmaceutical company, announced that the FDA has approved its Naloxone Auto-injector 10 mg (naloxone hydrochloride injection) indicated for the emergency treatment of people 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon, is suspected.